GlassScriptPhysician profile
Levi K Miller
NPI 1770713661
$2,558.96
in general payments reported to CMS, 2019-2025
33 companies · $446 in 2025
The $446 reported for 2025 was more than what 77% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $267 · 2021: $404 · 2022: $260 · 2023: $521 · 2024: $370 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.73 | 2021-2025 | |
| Saluda Medical Americas, INC. | $213.35 | 2024-2025 | Evoke |
| Pfizer INC. | $213.08 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $194.06 | 2019-2025 | Ztlido |
| Allergan, INC. | $168.73 | 2019-2022 | |
| Spr Therapeutics, INC | $140.06 | 2023-2025 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $99.84 | 2020-2021 | |
| Abbott Laboratories | $97.33 | 2023-2024 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $95.19 | 2019-2024 | Belbuca |
| Boston Scientific Corporation | $94.33 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept |
| Novartis Pharmaceuticals Corporation | $84.30 | 2019-2021 | |
| Lilly USA, LLC | $56.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.63 | 2022 | |
| Eisai INC. | $47.61 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.04 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $32.87 | 2019 | |
| Nalu Medical, INC. | $31.23 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.46 | 2019-2020 | |
| Axsome Therapeutics, INC. | $24.16 | 2025 | Symbravo |
| Lundbeck LLC | $23.85 | 2023 | Vyepti |
| Impel Pharmaceuticals INC. | $23.44 | 2022 | |
| Painteq LLC | $21.54 | 2024 | Painteq |
| Supernus Pharmaceuticals, INC. | $19.02 | 2021 | |
| Redhill Biopharma INC. | $17.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.70 | 2021 | |
| Amgen INC. | $17.18 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.43 | 2019 | |
| Shionogi INC | $14.92 | 2019 | |
| Biodelivery Sciences International, INC. | $14.66 | 2019 | |
| Curonix LLC | $14.30 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kaleo, INC. | $13.35 | 2019 | |
| Stimwave Technologies Incorporated | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.